NO20042056L - Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol - Google Patents

Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol

Info

Publication number: NO20042056L
Authority: NO; Norway
Prior art keywords: taxol; cox; inhibitor; treatment; pharmaceutical composition
Prior art date: 2001-10-19

Application number

NO20042056A

Other languages

English (en)

Inventor

Jonathan Green

Allan Lipton

Lois Mary Witters

Original Assignee

Lois Mary Witters

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-19

Filing date

2004-05-18

Publication date

2004-05-18

2004-05-18 Application filed by Lois Mary Witters filed Critical Lois Mary Witters

2004-05-18 Publication of NO20042056L publication Critical patent/NO20042056L/no

Links

229940122361 Bisphosphonate Drugs 0.000 title abstract 3
229930012538 Paclitaxel Natural products 0.000 title abstract 3
150000004663 bisphosphonates Chemical class 0.000 title abstract 3
229940111134 coxibs Drugs 0.000 title abstract 3
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 3
229960001592 paclitaxel Drugs 0.000 title abstract 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
230000036210 malignancy Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000003211 malignant effect Effects 0.000 abstract 2
208000006386 Bone Resorption Diseases 0.000 abstract 1
206010027452 Metastases to bone Diseases 0.000 abstract 1
230000024279 bone resorption Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20042056A 2001-10-19 2004-05-18 Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol NO20042056L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34592101P	2001-10-19	2001-10-19
PCT/EP2002/011696 WO2003035081A1 (en)	2001-10-19	2002-10-18	Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol

Publications (1)

Publication Number	Publication Date
NO20042056L true NO20042056L (no)	2004-05-18

Family

ID=23357099

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042056A NO20042056L (no)	2001-10-19	2004-05-18	Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol

Country Status (25)

Country	Link
US (1)	US7345088B2 (no)
EP (1)	EP1443942B1 (no)
JP (1)	JP2005506371A (no)
KR (1)	KR20040066103A (no)
CN (1)	CN100372539C (no)
AT (1)	ATE382347T1 (no)
AU (1)	AU2002363089B2 (no)
BR (1)	BR0213410A (no)
CA (1)	CA2461085A1 (no)
CO (1)	CO5570672A2 (no)
DE (1)	DE60224429T2 (no)
DK (1)	DK1443942T3 (no)
EC (1)	ECSP045054A (no)
ES (1)	ES2301710T3 (no)
HU (1)	HUP0402061A3 (no)
IL (2)	IL161090A0 (no)
MX (1)	MXPA04003671A (no)
NO (1)	NO20042056L (no)
NZ (1)	NZ532282A (no)
PL (1)	PL367707A1 (no)
PT (1)	PT1443942E (no)
RU (1)	RU2317819C2 (no)
SI (1)	SI1443942T1 (no)
WO (1)	WO2003035081A1 (no)
ZA (1)	ZA200402089B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0204756D0 (en) *	2002-02-28	2002-04-17	Novartis Ag	Organic compounds
GB0328040D0 (en) *	2003-12-03	2004-01-07	Coleman Robert E	Pharmaceutical uses of bisphosphonates
FR2939314A1 (fr) *	2008-12-04	2010-06-11	Univ Victor Segalen Bordeaux 2	Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
US9169279B2 (en)	2009-07-31	2015-10-27	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
US20160016982A1 (en)	2009-07-31	2016-01-21	Thar Pharmaceuticals, Inc.	Crystallization method and bioavailability
DK2459176T3 (en)	2009-07-31	2017-12-04	Gruenenthal Gmbh	Crystallization process and bioavailability
US9340565B2 (en)	2010-11-24	2016-05-17	Thar Pharmaceuticals, Inc.	Crystalline forms
US10195218B2 (en)	2016-05-31	2019-02-05	Grunenthal Gmbh	Crystallization method and bioavailability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1187130A (zh) *	1995-06-06	1998-07-08	麦克公司	用二磷酸盐预防与免疫抑制疗法有关的骨损失
CN1398189A (zh) *	1998-12-23	2003-02-19	G.D.西尔公司	用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
EP1253921A4 (en) *	2000-01-28	2004-10-13	Merck & Co Inc	TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS

2002
- 2002-10-18 IL IL16109002A patent/IL161090A0/xx unknown
- 2002-10-18 AU AU2002363089A patent/AU2002363089B2/en not_active Ceased
- 2002-10-18 ES ES02801899T patent/ES2301710T3/es not_active Expired - Lifetime
- 2002-10-18 PT PT02801899T patent/PT1443942E/pt unknown
- 2002-10-18 CA CA002461085A patent/CA2461085A1/en not_active Abandoned
- 2002-10-18 BR BR0213410-1A patent/BR0213410A/pt not_active IP Right Cessation
- 2002-10-18 DK DK02801899T patent/DK1443942T3/da active
- 2002-10-18 AT AT02801899T patent/ATE382347T1/de not_active IP Right Cessation
- 2002-10-18 RU RU2004115337/15A patent/RU2317819C2/ru not_active IP Right Cessation
- 2002-10-18 CN CNB028207823A patent/CN100372539C/zh not_active Expired - Fee Related
- 2002-10-18 US US10/493,042 patent/US7345088B2/en not_active Expired - Fee Related
- 2002-10-18 DE DE60224429T patent/DE60224429T2/de not_active Expired - Fee Related
- 2002-10-18 JP JP2003537648A patent/JP2005506371A/ja active Pending
- 2002-10-18 SI SI200230676T patent/SI1443942T1/sl unknown
- 2002-10-18 EP EP02801899A patent/EP1443942B1/en not_active Expired - Lifetime
- 2002-10-18 WO PCT/EP2002/011696 patent/WO2003035081A1/en not_active Ceased
- 2002-10-18 KR KR10-2004-7005630A patent/KR20040066103A/ko not_active Ceased
- 2002-10-18 PL PL02367707A patent/PL367707A1/xx not_active Application Discontinuation
- 2002-10-18 HU HU0402061A patent/HUP0402061A3/hu unknown
- 2002-10-18 MX MXPA04003671A patent/MXPA04003671A/es active IP Right Grant
- 2002-10-18 NZ NZ532282A patent/NZ532282A/en unknown
2004
- 2004-03-16 ZA ZA200402089A patent/ZA200402089B/en unknown
- 2004-03-25 IL IL161090A patent/IL161090A/en not_active IP Right Cessation
- 2004-04-08 EC EC2004005054A patent/ECSP045054A/es unknown
- 2004-04-15 CO CO04034537A patent/CO5570672A2/es not_active Application Discontinuation
- 2004-05-18 NO NO20042056A patent/NO20042056L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ATE382347T1 (de)	2008-01-15
NZ532282A (en)	2006-02-24
ES2301710T3 (es)	2008-07-01
BR0213410A (pt)	2004-11-03
DK1443942T3 (da)	2008-05-19
IL161090A (en)	2010-04-15
EP1443942A1 (en)	2004-08-11
JP2005506371A (ja)	2005-03-03
CN1703226A (zh)	2005-11-30
US20050014726A1 (en)	2005-01-20
ZA200402089B (en)	2005-06-22
CA2461085A1 (en)	2003-05-01
IL161090A0 (en)	2004-08-31
RU2317819C2 (ru)	2008-02-27
PL367707A1 (en)	2005-03-07
US7345088B2 (en)	2008-03-18
CO5570672A2 (es)	2005-10-31
PT1443942E (pt)	2008-04-07
HUP0402061A2 (hu)	2005-02-28
WO2003035081A1 (en)	2003-05-01
SI1443942T1 (sl)	2008-08-31
DE60224429D1 (de)	2008-02-14
HK1080733A1 (en)	2006-05-04
ECSP045054A (es)	2004-05-28
MXPA04003671A (es)	2005-06-20
EP1443942B1 (en)	2008-01-02
HUP0402061A3 (en)	2007-05-29
KR20040066103A (ko)	2004-07-23
DE60224429T2 (de)	2008-12-18
CN100372539C (zh)	2008-03-05
AU2002363089B2 (en)	2006-02-16
RU2004115337A (ru)	2005-04-20

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20034549L (no)	2003-10-09	Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
ATE366112T1 (de)	2007-07-15	Verwendung von zoledronsäure zur schmerzbehandlung
NO20063373L (no)	2006-09-21	CD40-antistoff-formuleringer og fremgangsmater
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
BR0116370A (pt)	2003-12-09	Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
EA200100572A1 (ru)	2002-02-28	Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
HUP0402506A2 (hu)	2005-04-28	FBPáz inhibitorok és inzulinérzékenység-fokozók kombinációja diabétesz kezelésére
BR0316458A (pt)	2005-10-11	Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0408491A (pt)	2006-04-04	tratamento da doença de alzheimer
DE60105025D1 (de)	2004-09-23	Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
BR0314081A (pt)	2005-07-05	Terapia de combinação compreendendo um bisfosfonato e um inibidor de hmg-coa redutase
BR0313081A (pt)	2005-07-12	Combinação de um inibidor de aromatase com um bisfosfanato
DK1443942T3 (da)	2008-05-19	Farmaceutisk sammensætning til anvendelse ved behandling af maligniteter omfattende en kombination af et bisphosphonat, en COX-2 inhibitor og en taxol
GB0020504D0 (en)	2000-10-11	Therapeutic method
JO3446B1 (ar)	2020-07-05	طريقة لمعالجة الأرق الأولي
SE0004827D0 (sv)	2000-12-22	Therapeutic compounds
BR0315374A (pt)	2005-08-23	Compostos orgânicos
DE69924385D1 (de)	2005-04-28	Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE392213T1 (de)	2008-05-15	Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen
BR0315376A (pt)	2005-08-23	Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor
BR0308105A (pt)	2005-01-04	Composição farmacêutica compreendendo um bisfosfonato e um inibidor de cox-2 para o tratamento de doenças de ossos
DK1007047T3 (da)	2006-05-08	Anvendelse af mizolastin til fremstilling af et lægemiddel beregnet til inflammationsbehandling
EA200600987A1 (ru)	2006-10-27	Применение сирамезина в лечении злокачественных опухолей
NO20051879L (no)	2005-04-18	Anvendelse av proteintyrosinfosfataseinhibitorer til forhindring og/eller behandling av kreft